WO1994026280A1 - Remedy for arthritis containing uridine as active ingredient - Google Patents

Remedy for arthritis containing uridine as active ingredient Download PDF

Info

Publication number
WO1994026280A1
WO1994026280A1 PCT/KR1993/000043 KR9300043W WO9426280A1 WO 1994026280 A1 WO1994026280 A1 WO 1994026280A1 KR 9300043 W KR9300043 W KR 9300043W WO 9426280 A1 WO9426280 A1 WO 9426280A1
Authority
WO
WIPO (PCT)
Prior art keywords
active ingredient
arthritis
remedy
lysine
peridine
Prior art date
Application number
PCT/KR1993/000043
Other languages
French (fr)
Japanese (ja)
Inventor
Hong Kuen Chung
Original Assignee
Korea Green Cross Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Green Cross Corporation filed Critical Korea Green Cross Corporation
Priority to PCT/KR1993/000043 priority Critical patent/WO1994026280A1/en
Priority to JP52525594A priority patent/JP3459013B2/en
Publication of WO1994026280A1 publication Critical patent/WO1994026280A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to a therapeutic agent for arthritis containing peridine as an active ingredient, and more particularly, to the use of a nucleoside, peridine, as a novel pharmacological effect for the treatment of phlegmitis and a drug containing the same. Things.
  • Urijin as four substances are distributed in Hiroshihan compassed in nature as one of ribonucleoside in nucleoside required to construct the RNA, its molecular weight is 244.20, molecular formula is C9H 12 N 2 0 6 10 And its structural formula is as follows:
  • ⁇ lysine has been used as a compound in combination with other pharmaceutical substances for vascular cerebral diseases, hepato-intestinal protection, peripheral hypertension, tissue hypoxia, etc. Its effect on treating arthritis is not known.
  • Figure 1 is a graph showing the time course of edema at the site of cataplasia in the control group and the group to which peridine was administered.
  • the present invention provides an agent for improving phlegmitis which contains pyridine, and when given 0.6 to 60 mg kg of pyridine, it has an excellent effect on Ifi phlegmitis.
  • the dispensing agent may be a dispensing agent such as a tablet, a liquid agent, a capsule agent, etc., which can be produced according to a commonly used method. Lactose, corn «flour, magnesium stearate and other excipients can do.
  • the present inventor has confirmed by experiments that perysin promotes cartilage formation, suppresses bone resorption (BONE RESORPTION), reduces tissue inflammation at section 88, and promotes regeneration.
  • collagen-induced arthritis (COLLAGEN-INDUCED ARTH RTTIS), which is a model for animal experiments on rheumatic malignant arthritis, was performed.
  • the rate of edema release at the site of M nodeitis is faster, and the degree of release of the final edema before being sacrificed also has a significant difference. It has been confirmed that the resulting tissue inflammation is reduced and the regeneration is promoted.
  • Collagen M-nodetitis is a type of autoimmune disease, and peridine is also effective in treating other autoimmune diseases.
  • Spleen K cells were obtained using a mesh with spleen K obtained by sacrificing two groups of rats. Each cell was suspended in Dulbecco's modified Idals medium containing 0.5% of the same group of blood. 2.5 ⁇ 10 6 spleen K cells were added, and collagen type ⁇ was added to make O g ml 0.01 g / ⁇ , 0.1 ⁇ g ml, 1 / ⁇ g ml, lO g ml. After leaving for 56 hours in the medium, 0.5 Ci-thymidine was added. After 16 hours, the seeds were harvested with an automatic harvester, and the radioactivity was measured with a scintillation counter.
  • an excipient incompatible with peridine was added according to the following composition and mixed to produce a tablet.

Abstract

A remedy for arthritis which contains uridine as the active ingredient and has an excellent efficacy.

Description

ゥリジンを有效成分とする關節炎治療劑  Remedies for arthritis containing peridine as an active ingredient
技術分野 Technical field
本發明はゥリジンを有效成分とする關節炎治療劑に關し,更に詳しくは，ヌク レオシドであるゥリジンの新規な藥效である翻節炎治療效果としての用途及びこれ を含有する藥劑に關するものである.  The present invention relates to a therapeutic agent for arthritis containing peridine as an active ingredient, and more particularly, to the use of a nucleoside, peridine, as a novel pharmacological effect for the treatment of phlegmitis and a drug containing the same. Things.
背景技術 Background art
ゥリジンは RNAを構成するのに必要な 4個のリボヌクレオシド中の一つとし て自然界で廣範圍に分布されている物質として，その分子量は 244.20であり， 分子式 は C9H12N206で 10あり，その構造式は次の通りだ. Urijin as four substances are distributed in Hiroshihan compassed in nature as one of ribonucleoside in nucleoside required to construct the RNA, its molecular weight is 244.20, molecular formula is C9H 12 N 2 0 6 10 And its structural formula is as follows:
Figure imgf000003_0001
Figure imgf000003_0001
OH OH 今まで知られたいるゥリジンの藥理作用はゥリジンが投與されると體內でゥリジン キナゼ酵素の «媒作用によってゥリジン 5' -ホスヌア-トへ直ちに 轉換されるので， 酵素の缺乏またはビリ ミジン ヌクレオ.チジト缺乏と核酸合成の缺乏に有用してオル チク酸尿症 (HEREDITARY OROTIC ACIDURIA)を輕滅させる藥劑として使われ た報告 (MATINDALE, 1989， 1627)があり，實際，大韓民國內にても複合製劑の成分 としているいるの藥效のため使用されたことがありますが,ゥリジン自體が關節炎に 效果を有することと報告されることはない. 本發明者は 生藥として使用されている 成分を研究する中， 單一成分として分離精製された各種物質の藥效スクリユングし た結果， 植物より分離された成分中の一が優れた關節炎治療效果を有することが發見 して， 該物質に對する分子構造を糾明した結果，ゥリジンであることを確認して本發 明を完成した. OH OH The known pharmacological action of ゥ lysine is that when ゥ lysine is administered, it is immediately converted to ゥ lysine 5'-phosphonate by the action of ゥ lysine quinase enzyme in the body, resulting in a lack of enzyme or bilimidine. There was a report (MATINDALE, 1989, 1627) that was used as a drug to reduce HEREDITARY OROTIC ACIDURIA, which is useful for nucleotidic deficiency and deficiency in nucleic acid synthesis (MATINDALE, 1989, 1627). Although it has been used as a component of the complex agent for its pharmaceutical effect, it has never been reported that peridine itself has an effect on arthritis. Of various substances separated and purified as single components As a result, it was found that one of the components isolated from the plant had an excellent effect of treating arthritis, and the molecular structure of the substance was clarified. Ming completed.
ゥリジンが今まで B藥品に使用された場合は他の藥效物質とともに複合製劑 として血管性腦疾患，肝腸保護,末梢祌經症,組織低酸素症等に使われることが知られて いるが,その關節炎治療效果は知られていない.  It has been known that 今 lysine has been used as a compound in combination with other pharmaceutical substances for vascular cerebral diseases, hepato-intestinal protection, peripheral hypertension, tissue hypoxia, etc. Its effect on treating arthritis is not known.
發明の 開示 Disclosure of invention
本發明の目的は，式  The purpose of this invention is
Figure imgf000004_0001
Figure imgf000004_0001
OH OH で表されるゥリジンを有效成分とする M節炎改善劑を提供するものである.  OH It is intended to provide an agent for improving M-inflammation containing peridine represented by OH as an active ingredient.
画面の簡單な說明  Easy explanation of screen
画 1は對照群と，ゥリジンを投與した群の翻節炎發生部位の浮腫が拔けるの經 時推移を表わされるグラフである.  Figure 1 is a graph showing the time course of edema at the site of cataplasia in the control group and the group to which peridine was administered.
發明を實施するための最良の形態  The best form for implementing the invention
本發明はゥリジンを有 分とする翻節炎改善劑を提供することでゥリジン 0.6 - 60mg kgを投與する場合， Ifi節炎に對する優れた效果を表わされる. それの有效 成分を經ロ投與するにあっては錠劑，液劑， カブセル劑等の投與製劑とすることがで き， これらは通常用いられる方法に從ぃ製造することができる. これらの製劑を製造 するために乳糖， とうもころし «粉， ステアリン酸 マグネシウム等の賦形劑を添加 することができる. The present invention provides an agent for improving phlegmitis which contains pyridine, and when given 0.6 to 60 mg kg of pyridine, it has an excellent effect on Ifi phlegmitis. The dispensing agent may be a dispensing agent such as a tablet, a liquid agent, a capsule agent, etc., which can be produced according to a commonly used method. Lactose, corn «flour, magnesium stearate and other excipients can do.
本發明者は實験によってゥリジンが軟骨形成を促進し， 骨吸收 (BONE RESORPTION)を抑制させて 88節で組織の炎症を低下させ，再生を促進する作用が冇 ることを確認した.  The present inventor has confirmed by experiments that perysin promotes cartilage formation, suppresses bone resorption (BONE RESORPTION), reduces tissue inflammation at section 88, and promotes regeneration.
卽ち，ゥリジンの關節炎の治療效果を確認するためにリュ -マチ性 M節炎の動 物實驗のモデルであるコラ-ゲン誘發 -M節炎實驗 (COLLAGEN-INDUCED ARTH RTTIS)を施行して對照群に比べて M節炎部位の浮腫が拔ける速度が早い,糧牲される 前までの最終浮腫の拔ける程度も有意の差を表わされる效果が有るのでゥリジンが コラ-ゲン關節炎が生ずる組織の炎症を低滅させ,再生を促進することを確認した. ま た,コラ-ゲン M節炎は自己免疫疾患の範 Wとして,ゥリジンがほかの自己免疫疾患の 治療にも效果が有ることと考える. ゥリジンに對する 毒性實驗の結果，元氣なラッ ト及びマウスにゥリジン 0.01, 0.1, 10， 100mg K ずつ投與し, 1週日以上観察した 所，とんなの異狀も發見かることができながったことを確認した.  In order to confirm the therapeutic effect of peridine on arthritis, collagen-induced arthritis (COLLAGEN-INDUCED ARTH RTTIS), which is a model for animal experiments on rheumatic malignant arthritis, was performed. Compared with the control group, the rate of edema release at the site of M nodeitis is faster, and the degree of release of the final edema before being sacrificed also has a significant difference. It has been confirmed that the resulting tissue inflammation is reduced and the regeneration is promoted. Collagen M-nodetitis is a type of autoimmune disease, and peridine is also effective in treating other autoimmune diseases. As a result of the toxicity experiment on lysine, 0.01, 0.1, 10, and 100 mg K of lysine were given to cheerful rats and mice, and when observed for more than 1 week, tongues and varieties were also found. I confirmed that I could not do it.
實施例 Practical example
以下， 實施例により本發明をさらに具體的に說明するが， 本發明はこれらによ り限定されるものではない.  Hereinafter, the present invention will be described more specifically with reference to practical examples, but the present invention is not limited thereto.
實施例 1. コラ -ゲン M節炎に對する藥效寅驗 Practical example 1. Pharmacological effect on collagen-M
(1)コラ -ゲン M節炎の誘導と観察  (1) Induction and observation of collagen-M ganglionitis
天然牛型 Πコラーゲン（Native bovine type Π collagen)を 2mg/mlなるように 溶解した後， 未完成のプロイント（Freund)坐薬とを 1:1で混合してェマルジョンを調 製した. このェマルジヨンをルイス ラットの尾根で lmlずつ皮下注射した. 8日後， 同一な方法だェマルジヨンを調製した後， lmlずつ腹腔內注射した. 以後， 開節炎が 發生したラット對照群と， ゥリジンを投與した群 (ゥリジン群 1は 10 gずつ一日あ たり 2回， ゥリジン群 2は lm ずつ一日あたり 2回)にてわけて觀察し，適當な間隔で闢 節炎が發生した足の厚さと廣さを測定した. また， コラ-ゲン タイ ·ΤΠに對する抗體 力價の經時變化を觀察するために一定間隔で 尾の靜脈で血淸を準備した. (2)コラ-ゲン タイプ Πに對する抗體カ價の經時變化の觀察 After dissolving Native bovine type Π collagen at a concentration of 2 mg / ml, it was mixed with unfinished Proint suppository at a ratio of 1: 1 to prepare an emulsion. Eight days later, an emulsion was prepared in the same manner, and then injected intraperitoneally in an amount of 1 ml. The rats were injected with lml intraperitoneally in the same manner.ゥ lysine group 1 was observed at 10 g twice a day and ゥ lysine group 2 twice a day lm). Blood was prepared at regular intervals in the tail vein to observe the time course of the body's resistance to collagen. (2) Observation on the time-dependent change of antibody value for collagen type Π
タナテク ィムロン 4 プレート（Danatech Immulon 4 plate)に各ウエノレ (wdl) 當 50 1のコラ-ゲン タイプ Π溶液 (10/ g ml)を添加し，一夜， コティングした後， また 一夜 3% BSA-PBS (bovine serum albumin-phosphate buffered saline)溶液 でブロキングした. このプレートをまず PBSで 4回洗滌し， 上記の ルイス ラットより 得た血清を添加した後，一夜， 反 ¾させた. その後 PBSで 4回洗准し，通酸化酵素を \ 標識したャギのアンティ-ラット ィムノグロブリン G(IgG)抗體を添加した. 一夜後， PBSで 4回洗滌し 0-フエ二レン ジァミンを基質として發色させた後， ETA ブレ- ト 判講器 (ETA plate reader)にて 405nmで R光度を測定した.  To a Danatech Immulon 4 plate, add 50% collagen type Π solution (10 / g ml) to each well (wdl), overnight, after coating and overnight, 3% BSA-PBS ( The plate was washed four times with PBS, and the serum obtained from the above-mentioned Lewis rat was added thereto, followed by incubating overnight. The plate was then washed four times with PBS. Then, goat anti-rat immunoglobulin G (IgG) antibody labeled with peroxidase was added. After one night, the plate was washed four times with PBS and developed with 0-phenylenediamine as a substrate. Then, the R luminous intensity was measured at 405 nm using an ETA plate reader (ETA plate reader).
(3) ¾-チミジン吸收分析  (3) ¾-thymidine absorption analysis
2つの群のラットを«牲させて得た脾 Kでメッシュを利用して脾 K細胞を得 た. 各各のゥヱルに 0.5%の同一群の血洧を含む Dulbecco修正 イダルス 培地に 浮遊 させた 2.5 X 106程度の脾 K細胞を入れて， コラ-ゲン タイプ Πを O g ml 0.01 g/ΐΐΑ, 0.1 ^ g ml, 1 /^ g ml, lO g mlなるようにいれた. 0¾ ィンキュベータの中で 56時間放置した後， 0.5 Ciの -チミジンを添加した. 16時間後， 自動收穫器にて 收種し， シンチレ-シヨン 計數管 (sdntillation counter)にて放射能を測定した. Spleen K cells were obtained using a mesh with spleen K obtained by sacrificing two groups of rats. Each cell was suspended in Dulbecco's modified Idals medium containing 0.5% of the same group of blood. 2.5 × 10 6 spleen K cells were added, and collagen type Π was added to make O g ml 0.01 g / ΐΐΑ, 0.1 ^ g ml, 1 / ^ g ml, lO g ml. After leaving for 56 hours in the medium, 0.5 Ci-thymidine was added. After 16 hours, the seeds were harvested with an automatic harvester, and the radioactivity was measured with a scintillation counter.
(4) 病理組織學的檢査 (4) Histopathological inspection
-チミジン吸收分析のためにルイス ラットを锾牲する時， »11節炎が發生し た後足をホルマリンで固定し， 無機物を除去してスライ ドを製作して病理組織學的 所見を觀察した.  When the Lewis rats were sacrificed for thymidine uptake analysis, the foot was fixed with formalin after »11 inflammation of the nodes, and the inorganic substance was removed to produce a slide and histopathological findings were observed. .
本實驗に對する結果は 節炎が發生した後， 一日 2回ずっゥリジンを投與した ルイス ラット群と蒸溜水たけを投與した群とのあいたには圆 1で表わされるように 關節炎が發生した足の浮腫 (edema)が拔ける程度と速度で有意の差が有することを認 められる. しかし 表 1と衷 2で示めしたように 2つの群のあいたに抗體カ慣の變化や 脾魔細胞の3 H-チミジン吸收の差はほどんとなかった. 病理組織學的の所見で， ゥリ ジンを投與したルイス ラッ トは蒸溜水を投與したラッ トの場合とは違く硝子軟骨 (hyaline cartilage)がたく さん殘ていり，纖維軟骨の形成ももつと活潑することとし た示めた. また， 炎症の所見は 2つの 群で,すべての部位によって程度の差を示めし たいるが，骨吸收の所見は蒸溜水を 投與した群のたけで示めることを確認される. 表 1. The results for this experiment show that after the onset of arthritis, the group of Lewis rats given lump lysine twice a day and the group given the distilled water as indicated by 關 1 were compared. It can be seen that there is a significant difference in the degree and speed at which the edema of the foot that developed is removed. However, as shown in Table 1 and Table 2, the change of the antibody mosquito between the two groups was observed. and the difference between the 3 H- thymidine absorption of脾魔cells ho was DONTO not. histopathological Manabu basis of the findings, Lewis rats were ToAtae the © Li Jin in the case of the rats that were ToAtae distilled water Differently hyaline cartilage (hyaline cartilage) remained, indicating that it also had an effect on the formation of fibrocartilage. The findings of inflammation were of two groups and showed varying degrees at all sites. However, it was confirmed that bone resorption findings could be shown by the group fed distilled water. Table 1.
2つの群の抗體カ價の經時變化  Changes in Antibody Value of Two Groups
B ゥリジン群 B ゥ Lysine group
ラ ト 1 ラット 2 ラウト 1 ' ラウト 2 ラウ卜  Rat 1 rat 2 route 1 'route 2 route
1 0 0 0 0 0 1 0 0 0 0 0
9 1/1600 1/400 1/400 1/400 1/600  9 1/1600 1/400 1/400 1/400 1/600
15 1/3200 1/800 1/1600 1/1600 1/1200  15 1/3200 1/800 1/1600 1/1600 1/1200
22 X* 1/3200 1/2400 1/2400 1/3200  22 X * 1/3200 1/2400 1/2400 1/3200
28 X X 1/3200 1/3200 X  28 X X 1/3200 1/3200 X
37 X 1/3200 1/2400 1/3200 X  37 X 1/3200 1/2400 1/3200 X
48 X 1/3200 1/2400 1/1600 X  48 X 1/3200 1/2400 1/1600 X
53 X 1/1600 1/2400 1/1600 X  53 X 1/1600 1/2400 1/1600 X
58 X 1/1600 1/2400 1/1600 X  58 X 1/1600 1/2400 1/1600 X
67 X 1/1600 1/2400 1/800 X  67 X 1/1600 1/2400 1/800 X
* Xは抗體カ憤が 1/3200以上ですのでそれより測定しなかったのを意味. * X means that we did not measure any more than 1/3200, because the anti-angry is more than 1/3200.
表 2 2つの群の脾 K細胞の增殖分析 Table 2 Proliferation analysis of splenic K cells in two groups
96ゥエルの »照群 (cpm) ゥリジン群 (cpai) 96 ゥ L »Sh 照 group (cpm) ゥ Lysine group (cpai)
コラ-ゲン濃度 ラ ト 1 ラウト 2 ラヅ ト 1 ラウ卜 2 ラッ卜 3  Collagen concentration Rat 1 Rat 2 Rat 1 Rat 2 Rat 3
10 / g/nl 9582 5441 8746 7050 6164 10 / g / nl 9582 5441 8746 7050 6164
5210 4688 7756 4231 4377 5210 4688 7756 4231 4377
0.1 g/ml 3588 4916 4482 4441 34850.1 g / ml 3588 4916 4482 4441 3485
0.01 ^ ml 4236 5042 4510 3691 35010.01 ^ ml 4236 5042 4510 3691 3501
0 /g/nl 7241 4452 6483 6649 4965 0 / g / nl 7241 4452 6483 6649 4965
* 上記の cpmは同一條件の 6個ゥヱルの cpm値の平均値. 實施例 2.藥劑學的綻劑の製造 * The above cpm is the average value of cpm value of 6 pcs under the same condition.
(1)通常の方法に從つてゥリジンの藥效にさしつかえない賦形劑を下記の 組 成に依って添加し， 混合して錠劑を製造した.  (1) In accordance with the usual method, an excipient incompatible with peridine was added according to the following composition and mixed to produce a tablet.
組成 ：  Composition:
ゥリジン 1 mg  Perlysine 1 mg
とうもころし «粉 27 mg  Corn «27 mg powder
乳糖 40 mg  Lactose 40 mg
ステアリン酸 マグネシウム 2 mg  Magnesium stearate 2 mg
1 錠當 70 mg (2) 通常の方法に従って下記の 組成に依って錠劑を製造した. 組成 ： ゥリジン 5 mg 1 tablet 70 mg (2) A tablet was produced according to the following composition according to the usual method. Composition: Perlysine 5 mg
とうもころし «粉 25 mg 乳糖 38 mg ステアリン酸 マグネシウム 2 mg  Corn «Powder 25 mg Lactose 38 mg Magnesium stearate 2 mg
1 70 mg  1 70 mg

Claims

特許請求の範圍 The scope of the claims
(1) ゥリジンを有效成分とする M節炎治療劑.  (1) A therapeutic agent for M-nodetitis containing peridine as an active ingredient.
(2) 前記の製劑が錠劑であることを特徴とする請求項 1記載の M節炎治療劑.  (2) The agent for treating M-nodetitis according to claim 1, wherein the agent is a tablet.
PCT/KR1993/000043 1993-05-19 1993-05-19 Remedy for arthritis containing uridine as active ingredient WO1994026280A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/KR1993/000043 WO1994026280A1 (en) 1993-05-19 1993-05-19 Remedy for arthritis containing uridine as active ingredient
JP52525594A JP3459013B2 (en) 1993-05-19 1993-05-19 An agent for treating arthritis containing uridine as an active ingredient

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR1993/000043 WO1994026280A1 (en) 1993-05-19 1993-05-19 Remedy for arthritis containing uridine as active ingredient

Publications (1)

Publication Number Publication Date
WO1994026280A1 true WO1994026280A1 (en) 1994-11-24

Family

ID=19349351

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR1993/000043 WO1994026280A1 (en) 1993-05-19 1993-05-19 Remedy for arthritis containing uridine as active ingredient

Country Status (2)

Country Link
JP (1) JP3459013B2 (en)
WO (1) WO1994026280A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790348A2 (en) * 1999-05-05 2007-05-30 Srinivas Uppugunduri Use of uridine for the treatment of inflammations and/or hemostasis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60136515A (en) * 1983-12-23 1985-07-20 Yasuo Komoda Hypnotic agent
JPS62145019A (en) * 1985-12-19 1987-06-29 Senjiyu Seiyaku Kk Anti-inflammatory agent
JPH0245425A (en) * 1988-06-21 1990-02-15 Polifarma Spa Drug for treatment of brain nerve disorder
JPH04243830A (en) * 1990-06-13 1992-08-31 Polifarma Spa Uridine used for curing pharmacologically peripheral complication of diabetes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60136515A (en) * 1983-12-23 1985-07-20 Yasuo Komoda Hypnotic agent
JPS62145019A (en) * 1985-12-19 1987-06-29 Senjiyu Seiyaku Kk Anti-inflammatory agent
JPH0245425A (en) * 1988-06-21 1990-02-15 Polifarma Spa Drug for treatment of brain nerve disorder
JPH04243830A (en) * 1990-06-13 1992-08-31 Polifarma Spa Uridine used for curing pharmacologically peripheral complication of diabetes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CLINICAL SCIENCE, Vol. 74, No. 1, (1988), K.E. HERBERT et al., "Nucleosides and Bases in Synovital Fluid from Patients with Rheumatoid Arthritis and Osteoarthritis", p. 97-99. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790348A2 (en) * 1999-05-05 2007-05-30 Srinivas Uppugunduri Use of uridine for the treatment of inflammations and/or hemostasis
US7687476B2 (en) 1999-05-05 2010-03-30 Srinivas Uppugunduri Specific inhibitors of acute and chronic inflammation

Also Published As

Publication number Publication date
JP3459013B2 (en) 2003-10-20

Similar Documents

Publication Publication Date Title
Ragan et al. Effect of cortisone on production of granulation tissue in the rabbit.
DE69926750T2 (en) PREVENTING THE BRAIN INFINE BY COMBINED ADMINISTRATION OF ADP RECEPTOR ANTIBLE PLATES AND ANTI-HYPERTENSIVE MEDICAMENTS
CN104127859B (en) The application of polypeptide in preparation treatment or prevention medicine for treating rheumatoid arthritis
KR920702383A (en) Biocorrosive polymers useful for controlling the release of therapeutic agents
JPH06507635A (en) Compositions for the prevention and/or treatment of pathological processes
DE112011102350T5 (en) A combination pharmaceutical composition and method for treating disorders of the genitourinary system
Akutsu et al. Antibody against interleukin-5 prevents antigen-induced eosinophil infiltration and bronchial hyperreactivity in the guinea pig airways
JPH11507044A (en) Bisphosphonates prevent bone loss associated with immunosuppressive therapy
Herdman et al. Anticoagulants in renal disease in children
AU2020353038A1 (en) Use of CD200 protein and CD200 fusion protein in preparing a drug for treating psoriasis
Critchley et al. Granulocyte-colony stimulating factor in the treatment of colchicine poisoning
US20100130604A1 (en) Use of rosmarinic acid in manufacture of medicaments for treating or preventing hepatic and renal diseases
WO1997038693A1 (en) Calcium channel blockers as human conjunctival mast cell degranulation inhibitors for treating ocular allergic conditions
DE3830271A1 (en) MEDIUM WITH IMMUNE SUPPRESSIVE EFFECT
KR100533399B1 (en) Oral Administration
AU2008265974B2 (en) Use of TACI-Ig fusion protein such as atacicept for the manufacture of a medicament for treating Lupus Erythematosus
WO1994026280A1 (en) Remedy for arthritis containing uridine as active ingredient
Nitti et al. Pharmacokinetic study of intravenous rifampicin
Arter et al. EXPERIENCE WITH THE USE OF 6‐MERCAPTOPURINE AND “IMURAN” IN THE TREATMENT OF PROGRESSIVE HEPATITIS (ACTIVE CHRONIC HEPATITIS)
CA2226340A1 (en) Drug for ameliorating brain diseases
PRESTON et al. Clinical use of the anticoagulant phenylindanedione: report of 74 cases
KR100318519B1 (en) Arthritis curing agent including uracil as active ingredient
JPS59110621A (en) Diuretic
KR940008033B1 (en) Antiarthritis agent containing uridine
US4302452A (en) Use of derivatives of 6α-methylprednisolone as an antiemetic

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): DE JP US

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642